Abstract: It is described here a cosmetic composition and its use for the reduction of dermatological disorders resulting from the use of alpha-hydroxy acids (AHAs), while maintaining their effectiveness in the cell renewal process. In particular, said composition comprises one or more AHA compounds as active ingredients, wherein preferably the AHA compounds are glycolic acid, lactic acid, mandelic acid and malic acid. Additionally, said composition comprises one or more polyhydroxy acid (PHAs) compounds, wherein preferably the PHA compound is lactobionic acid.

Abstract: The present invention describes new derivatives of S-allylcysteine with antioxidant and antiaging activity. Said derivatives can be used alone or in a combined formulation with other compounds with known activity.

Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

Abstract: A cosmetic composition and its use as an antioxidant and bleaching agent is described. In particular, said composition comprises different active ingredients, among them a botanical extract, and cosmetically acceptable excipients. The active compounds are selected from ferulic acid, olive leaves extract, maslinic acid, Octadecyl Di-t-butyl-4-hydroxyhydrocinnamate and BHT.

Abstract: The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

Abstract: Presented in this utility model, belonging to the pharmaceutical field, a facilitator kit for the co-administration of drugs for the treatment of Helicobacter pylori infections.

Abstract: The present invention relates to a liquid pharmaceutical composition for oral administration and its use, wherein said composition comprises: (i) a therapeutically effective amount of desloratadine or a pharmaceutically acceptable salt thereof; (ii) a therapeutically effective amount of prednisolone or a pharmaceutically acceptable salt thereof; (iii) a set of pharmaceutically acceptable excipients wherein the employed flavoring agent excipient being free of vanillin or a derivative thereof, and wherein the pH of said composition is maintained at a value in the range between 6.0 and 7.5. In the preferred embodiment, the composition of the invention is an antihistaminic composition for oral administration in the form of sugar-free syrups, intended for pediatric use.

Abstract: The present invention describes novel and improved parenteral depot pharmaceutical compositions containing cosyntropin (tetracosactide), for the treatment of infantile spasm.

Abstract: The present invention aims to provide reduction of localized fat, particularly for the treatment, prevention or alleviation of gynoid lypodystrophy. The cosmetic composition of the invention comprises: (a) from 4.0 to 27.0% by weight of active ingredients comprising: (i) at least one localized fat reducing agent selected from the group consisting of natural, modified and synthetic substances, (ii) at least one alkaloid, (iii) at least one oil or vegetable extract, (iv) at least one antioxidant, and (v) at least one film forming agent; (b) 6.0 to 32.0% by weight of cosmetically acceptable additives; and (c) q.s.p. 100% by weight of hydrophilic gel-cream base. The invention also comprises a gel-cream formulation for localized fat reduction, as well as the use of said composition or formulation for manufacturing of a cosmetic for the treatment, prevention or alleviation of gynoid lypodystrophy.

Abstract: The present invention relates to the field of food and medicines for the treatment or alleviation of premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), premenopause, menopause and female hormonal disorders. A first embodiment relates to a composition containing vitamins, minerals and oils. Additionally, the invention comprises a pharmaceutical form, more specifically in the form of soft capsules (also known as gelatin) containing the composition of the invention. In particular, the compositions of the invention contain vitamins and minerals in sources compatible with the association of vegetable oils, preferably borage oil, evening primrose oil, or a mixture of two oils, wherein the soft capsule contains a liquid and oily core.

Abstract: The present invention aims to provide a solid pharmaceutical composition comprising: (a) an effective antibacterial quantity of antibiotic from the quinolone family, preferably, moxifloxacin or a pharmaceutically acceptable salt thereof; and (b) a pharmacologically acceptable carrier or excipient compatible with the active ingredient, said excipient being lactose-free. The invention also includes a process for obtaining a solid pharmaceutical composition comprising, as an active ingredient, an antibiotic from the quinolone family, with said process comprising the steps of: (a) mixing and homogenizing the active ingredient and dry excipients in the granulator, i.e.

Abstract: The present invention describes antihypertensive pharmaceutical formulations particularly formulations of losartan and indapamide.